49,006
edits
Difference between revisions of "Malignant mesothelioma"
Jump to navigation
Jump to search
Malignant mesothelioma (view source)
Revision as of 19:53, 18 December 2024
, 19:53, 18 December 2024no edit summary
| (One intermediate revision by the same user not shown) | |||
| Line 145: | Line 145: | ||
**D2-40. | **D2-40. | ||
**[[CK5/6]]. | **[[CK5/6]]. | ||
**[[CA-125]].<ref name=pmid9023557>{{cite journal |authors=Bateman AC, al-Talib RK, Newman T, Williams JH, Herbert A |title=Immunohistochemical phenotype of malignant mesothelioma: predictive value of CA125 and HBME-1 expression |journal=Histopathology |volume=30 |issue=1 |pages=49–56 |date=January 1997 |pmid=9023557 |doi=10.1046/j.1365-2559.1996.d01-562.x |url=}}</ref> | |||
*Carcinoma markers: | *Carcinoma markers: | ||
**CEA (monoclonal and polyclonal). | **CEA (monoclonal and polyclonal). | ||
**[[TTF-1]]. | **[[TTF-1]]. | ||
**[[Ber-EP4]]. | **[[Ber-EP4]]. | ||
**100% of lung adenocarcinoma versus ~25% of mesotheliomas.<ref>{{cite journal |authors=Ordóñez NG |title=Value of the Ber-EP4 antibody in differentiating epithelial pleural mesothelioma from adenocarcinoma. The M.D. Anderson experience and a critical review of the literature |journal=Am J Clin Pathol |volume=109 |issue=1 |pages=85–9 |date=January 1998 |pmid= |doi=10.1093/ajcp/109.1.85 |url=}}</ref> | ***100% of lung adenocarcinoma versus ~25% of mesotheliomas.<ref>{{cite journal |authors=Ordóñez NG |title=Value of the Ber-EP4 antibody in differentiating epithelial pleural mesothelioma from adenocarcinoma. The M.D. Anderson experience and a critical review of the literature |journal=Am J Clin Pathol |volume=109 |issue=1 |pages=85–9 |date=January 1998 |pmid= |doi=10.1093/ajcp/109.1.85 |url=}}</ref> | ||
**MOC-31. | **MOC-31. | ||
**CD15. | **CD15. | ||